Views: 166 Author: Site Editor Publish Time: 2024-04-09 Origin: Site
The 2024 BIO International Convention serves as the most influential gathering for the global biotechnology industry, providing a unique platform for companies to showcase innovations, forge partnerships and advance drug development. For the autoimmune disease sector, which affects over 23.5 million people in the United States alone, this year's event is particularly significant as it features dedicated tracks on preclinical research, translational medicine and novel immunotherapies.
With the global autoimmune disease drug market projected to grow steadily in the coming years, there is an urgent need for more reliable preclinical tools to address the high clinical failure rate of drug candidates. BIO 2024 will host over 300 scientific sessions addressing key challenges in autoimmune drug development, including model validation, efficacy testing and regulatory compliance, making it an ideal venue for HKeybio to share its specialized expertise.
HKeybio has established itself as a trusted global partner for autoimmune drug development, with a core technical team possessing over 20 years of comprehensive experience in the entire autoimmune drug R&D chain. The company has obtained ISO9001 quality system certification, ensuring consistent and high-quality research services.
HKeybio's core capabilities include:
50+ Validated NHP Models: Covering major autoimmune and allergic conditions, providing high clinical relevance for immunotherapy evaluation
500+ Autoimmune & Allergic Disease Animal Models: A diverse portfolio of rodent models tailored to various research needs
End-to-End In Vivo Efficacy Services: From custom model generation to comprehensive efficacy testing and data analysis
A key differentiator for HKeybio is its extensive experience supporting IND submissions. The team has accumulated over 300 successful IND filing experiences for autoimmune diseases, enabling it to efficiently address various challenges in the drug development and regulatory approval process. This proven track record has made HKeybio a preferred partner for pharmaceutical companies looking to accelerate their preclinical programs.
"We are excited to participate in BIO 2024 and connect with global partners who share our commitment to advancing autoimmune disease treatments," said Dr. Zhao, CEO of HKeybio. "Our specialized focus on autoimmune and allergic diseases, combined with our comprehensive model resources and regulatory expertise, allows us to deliver high-quality preclinical data that supports successful IND submissions."
